James Waddington

Mr. James Waddington

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2016 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
XMXiaoli Meng
Xiaoli Meng
CECaroline J. Earnshaw
Caroline J. Earnshaw
ATArun Tailor
Arun Tailor
RJRosalind E. Jenkins
Rosalind E. Jenkins
JWJames Waddington
James Waddington
BPB. Kevin Park
B. Kevin Park

30 September 2016 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
ATArun Tailor
Arun Tailor
JWJames Waddington
James Waddington
XMXiaoli Meng
Xiaoli Meng
BPB. Kevin Park
B. Kevin Park

31 July 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XMXiaoli Meng
Xiaoli Meng
JWJames Waddington
James Waddington
ATArun Tailor
Arun Tailor
ALAdam Lister
Adam Lister
JHJane Hamlett
Jane Hamlett
MSMichael B. Sporn
Michael B. Sporn

29 July 2020 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
JWJames Waddington
James Waddington
XMXiaoli Meng
Xiaoli Meng
PIPatricia T Illing
Patricia T Illing
ATArun Tailor
Arun Tailor
KAKareena Adair
Kareena Adair
BPBrian Kevin Park
Brian Kevin Park
Flucloxacillin is a β-lactam antibiotic associated with a high incidence of drug-induced liver reactions. Although expression of human leukocyte antigen (HLA)-B*57:01 increases susceptibility, little is known of the pathological mechanisms involved in the induction of the clinical phenotype. Irreversible protein modification is suspected to drive the reaction through the modification of peptides that are presented by the risk allele. In this study, the binding of flucloxacillin to immune cells was characterized and the nature of the peptides presented by HLA-B*57:01 was analyzed using mass spectrometric-based immunopeptidomics methods. Flucloxacillin modification of multiple proteins was observed, providing a potential source of neoantigens for HLA presentation. Of the peptides eluted from flucloxacillin-treated C1R-B*57:01 cells, 6 putative peptides were annotated as flucloxacillin-modified HLA-B*57:01 peptide ligands (data are available via ProteomeXchange with identifier PXD020137). To conclude, we have characterized naturally processed drug-haptenated HLA ligands presented on the surface of antigen presenting cells that may drive drug-specific CD8+ T-cell responses.

24 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
RGRobert Gurke
Robert Gurke
ABAnnika Bendes
Annika Bendes
JBJohn Bowes
John Bowes
MKMichaela Köhm
Michaela Köhm
RTRichard Twyman
Richard Twyman
Stephen PenningtonStephen Pennington
Stephen Pennington
The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients.

31 October 2017 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
AAAbdulaziz Alzahrani
Abdulaziz Alzahrani
MOMonday Ogese
Monday Ogese
XMXiaoli Meng
Xiaoli Meng
JWJames Waddington
James Waddington
ATArun Tailor
Arun Tailor
DNDean Naisbitt
Dean Naisbitt